Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Related Clinical Trial
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia AML Therapy With Irradiated Allogeneic Cells Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Brief Title

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Official Title

Vitamin D3 Supplementation in Acute Myeloid Leukemia: Pharmacokinetic Study

Brief Summary

      This partially randomized phase II trial studies the side effects and best way to give and
      best dose of cholecalciferol in treating patients with acute myeloid leukemia (AML)
      undergoing intensive induction chemotherapy. Cholecalciferol may help improve the outcome of
      patients with AML undergoing intensive chemotherapy
    

Detailed Description

      PRIMARY OBJECTIVES: I. To assess patients with regards to changes in 25(OH)-D3 changes after
      supplementation. II. To develop a pharmacokinetic model to describe the time course of the
      relationship of vitamin D3 (cholecalciferol) supplementation that drives the levels of
      25(OH)-D3 during the intensive induction chemotherapy. III. To determine the safety and
      toxicity of vitamin D3 supplementation in AML patients undergoing intensive induction
      chemotherapy. SECONDARY OBJECTIVES: I. To explore whether rapid (loading dose of vitamin D3)
      normalization of 25(OH)-D3 levels will have an effect on the progression free and overall
      survival. II. To explore whether a relationship exists between the pharmacokinetics of the
      25-hydroxy-vitamin D3 and white blood cell count. OUTLINE: Patients with pretreatment
      25(OH)-D3 levels 20-31.9 ng/mL (insufficient levels) are randomized to 1 of 2 treatment arms.
      ARM I: Patients receive a loading dose of cholecalciferol orally (PO) on day 1. Patients then
      receive lower-dose cholecalciferol PO beginning on day 8. ARM II: Patients receive a loading
      dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO
      beginning on day 8. Patients with pretreatment 25(OH)-D3 levels < 20 ng/mL (deficient levels)
      receive a loading dose of cholecalciferol PO on days 1 and 8. Patients then receive
      lower-dose cholecalciferol PO beginning on day 15. For all patients, treatment continues in
      the absence of disease progression or unacceptable toxicity. After completion of study
      treatment, patients are followed up at 30 days.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Changes in 25(OH)-D3 levels after supplementation


Condition

Adult Acute Megakaryoblastic Leukemia (M7)

Intervention

cholecalciferol

Study Arms / Comparison Groups

 Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])
Description:  Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Dietary Supplement

Estimated Enrollment

4

Start Date

December 2011

Completion Date

June 2015

Primary Completion Date

March 2013

Eligibility Criteria

        Inclusion Criteria: Pathologic diagnosis of newly diagnosed AML (excluding acute
        promyelocytic leukemia [APL]) Patients undergoing intensive induction therapy (equivalent
        of 7+3, cytarabine, daunorubicin, etoposide [ADE] or high-dose cytarabine containing
        regimens) Subnormal 25(OH)-D3 levels (< 32 ng/mL) Serum calcium =< upper limit of normal
        Demonstrate the ability to swallow and retain oral medication Patients of child-bearing
        potential must agree to use acceptable contraceptive methods (e.g., double barrier) during
        treatment Patient or legal representative must understand the investigational nature of
        this study and sign an Independent Ethics Committee/Institutional Review Board approved
        written informed consent form prior to receiving any study related procedure Exclusion
        Criteria: Patients should not have a history of nephrocalcinosis Patients should not have
        received bisphosphonate treatment within 28 days before study entry Pregnant or nursing
        female patients Unwilling or unable to follow protocol requirements Any condition which in
        the Investigator's opinion deems the patient an unsuitable candidate to receive study drug
        Received an investigational agent within 30 days prior to enrollment Patients who cannot be
        discontinued from cimetidine, thiazide diuretics and/or heparin Patients who are on
        magnesium based antacids who cannot be offered an alternative regimen
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Meir Wetzler, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01521936

Organization ID

I 201311

Secondary IDs

NCI-2011-03554

Responsible Party

Sponsor

Study Sponsor

Roswell Park Cancer Institute

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Meir Wetzler, Principal Investigator, Roswell Park Cancer Institute


Verification Date

June 2015